Company Filing History:

15 out of 318

Taiho Pharmaceutical Company Limited

where one patent can have more than one assignee

Years Active: 1982-1996

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 5571914 - 4-desoxy-4-epipodophyllotoxin derivative or pharmaceutically acceptable (1996-11-05),

2. 5536847 - 4-desoxy-4-epipodophyllotoxin derivative or pharmaceutically acceptable (1996-07-16),

3. 5489698 - 4-Desoxy-4-epipodophyllotoxin derivative or pharmaceutically acceptable (1996-02-06),

4. 5420117 - 5-substituted uridine derivatives (1995-05-30),

5. 5250673 - 2'-deoxy-5-substituted uridine derivatives (1993-10-05),

6. 5032680 - 2'-deoxy-5-fluorouridine derivatives (1991-07-16),

7. 4946951 - 2'-deoxy-5-fluorouridine derivatives (1990-08-07),

8. 4897503 - 1,1,2-triaryl-1-alkene derivatives (1990-01-30),

9. 4886877 - Novel 2'-deoxy-5-substituted uridine derivatives, processes for (1989-12-12),

10. 4719213 - Anti-cancer composition for delivering 5-fluorouracil (1988-01-12),

11. 4652570 - Anti-cancer composition for delivering 5-fluorouracil (1987-03-24),

12. 4650801 - Anti-cancer compositions for delivering 5-fluorouracil (1987-03-17),

13. 4622325 - Anti-cancer composition for delivering 5-fluorouracil (1986-11-11),

14. 4507301 - Anti-cancer composition for delivering 5-fluorouracil (1985-03-26),

15. 4481203 - Composition containing 1-(n-hexylcarbamoyl)-5-fluorouracil and uracil (1984-11-06),

Title: The Contributions of Inventor Setsuo Takeda

Introduction

Setsuo Takeda is a prominent inventor hailing from Tokushima, Japan. With an impressive portfolio of 16 patents, his work primarily focuses on innovative pharmaceutical compounds. Takeda's contributions have significantly impacted the field of medicine, especially in developing antitumor therapies.

Latest Patents

Among his latest inventions is a 4-desoxy-4-epipodophyllotoxin derivative, described as a vital pharmaceutical compound. The patented formula, which includes R and R1 variables defined in the specification, can also exist in pharmaceutically acceptable salt forms. This innovative derivative is encapsulated within an antitumor composition, showcasing its effectiveness in the medical field.

Career Highlights

Setsuo Takeda has been instrumental in the research and development sectors of esteemed companies, including Taiho Pharmaceutical Company Limited and Kuraray Co., Ltd. His extensive experience has enabled him to make significant advancements in pharmaceuticals, contributing to various therapeutic applications.

Collaborations

Throughout his career, Takeda has collaborated with notable professionals, including Norio Unemi and Setsuro Fujii. These partnerships have fostered innovation and creative solutions, enhancing the spectrum of therapeutic options available through his recognized inventions.

Conclusion

Setsuo Takeda's body of work exemplifies the essence of innovation in pharmaceutical sciences. His dedication to refining antitumor treatments through his patented inventions signifies his status as a remarkable inventor, making strides toward improving healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com